NextCell Pharma AB
Research NextCell Pharma AB (NXTCL) on Bullrun: market cap SEK 149.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNXTCL
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 149.14M
- Financial periodQ1 2026
- RevenueSEK 2.78M
- Net income-SEK 10.39M
- Gross margin34.5%
Valuation Snapshot
latest market cap is SEK 149.14M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 9.54M | -SEK 42.53M | n/a | 8.5% | n/a | SEK 38.72M | n/a | SEK 41.09M |
| FY2024 | SEK 11.56M | -SEK 41.18M | n/a | -29.9% | n/a | SEK 34.12M | n/a | SEK 59.56M |
| FY2023 | SEK 13.95M | -SEK 39.82M | n/a | 21.1% | n/a | SEK 50.03M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | SEK 149.14M | n/a | n/a | n/a |
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NextCell Pharma AB's market cap?
NextCell Pharma AB's market capitalization is SEK 149.14M.
What does NextCell Pharma AB do?
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.